29 May 2019 - Canada has a long history of the use of clinical evidence to support health care decision making. 

Given improvements in data holdings and analytic capacity in Canada and stakeholder interest, the purpose of this study is to reflect on perceptions of the value of real-world evidence in pricing and reimbursement decisions, barriers to its optimal use in pricing and reimbursement, current initiatives that may lead to its increased use, and what role the pharmaceutical industry may play in this.

The use of real world data in Canada to inform pricing and reimbursement decisions is far from routine but nascent and slowly increasing.

Read International Journal of Technology Assessment in Health Care article